Leukemia treatment in severe combined immunodeficiency mice by antisense oligodeoxynucleotides targeting cooperating oncogenes

doi:10.1084/jem.182.6.1645

This Article

	Full Text (PDF)
	Alert me when this article is cited
	Citation Map

Services

	Email this article
	Similar articles in this journal
	Similar articles in PubMed
	Alert me to new content in the JEM
	Download to citation manager

Citing Articles

	Citing Articles via HighWire
	Citing Articles via CrossRef
	Citing Articles via Google Scholar

Google Scholar

	Articles by Skorski, T.
	Articles by Calabretta, B.
	Search for Related Content

PubMed

	PubMed Citation
	Articles by Skorski, T.
	Articles by Calabretta, B.


Social Bookmarking

	What's this?

ARTICLES

Leukemia treatment in severe combined immunodeficiency mice by antisense oligodeoxynucleotides targeting cooperating oncogenes

T Skorski, M Nieborowska-Skorska, K Campbell, RV Iozzo, G Zon, Z Darzynkiewicz and B Calabretta
Jefferson Cancer Institute, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA.

Transformation of hematopoietic cells by the p210bcr/abl tyrosine kinase appears to require the expression of a functional MYC protein, suggesting that simultaneous targeting of BCR-ABL and c-myc might be a rational strategy for attempting treatment of Phil-adelphia leukemia. To test this hypothesis, severe combined immunodeficiency mice injected with Philadelphia leukemic cells were treated systemically with equal doses of bcr-abl or c-myc antisense oligodeoxynucleotides (ODNs) or with both ODNs in combination. Compared with the mice treated with individual agents, the disease process was much slower in the group treated with both ODNs, as revealed by flow cytometry, clonogenic assay, and reverse transcriptase-polymerase chain reaction analysis to detect leukemic cells in mouse tissue cell suspensions, and by enumeration of liver metastases. The retardation of the disease process was positively correlated with a markedly increased survival of leukemic mice treated with both ODNs. These data demonstrate the therapeutic potential of targeting multiple cooperating oncogenes.
Add to CiteULike CiteULike Add to Complore Complore Add to Connotea Connotea Add to Del.icio.us Del.icio.us Add to Digg Digg Add to Reddit Reddit Add to Technorati Technorati What's this?

This article has been cited by other articles:

Parreno, M., Vaque, J. P., Casanova, I., Frade, P., Cespedes, M. V., Pavon, M. A., Molins, A., Camacho, M., Vila, L., Nomdedeu, J. F., Mangues, R., Leon, J. (2006). Novel triiodophenol derivatives induce caspase-independent mitochondrial cell death in leukemia cells inhibited by Myc. Molecular Cancer Therapeutics 5: 1166-1175 [Abstract] [Full Text]
Yang, S., Chintapalli, J., Sodagum, L., Baskin, S., Malhotra, A., Reiss, K., Meggs, L. G. (2005). Activated IGF-1R inhibits hyperglycemia-induced DNA damage and promotes DNA repair by homologous recombination. Am. J. Physiol. Renal Physiol. 289: F1144-F1152 [Abstract] [Full Text]
Carbone, G. M., McGuffie, E., Napoli, S., Flanagan, C. E., Dembech, C., Negri, U., Arcamone, F., Capobianco, M. L., Catapano, C. V. (2004). DNA binding and antigene activity of a daunomycin-conjugated triplex-forming oligonucleotide targeting the P2 promoter of the human c-myc gene. Nucleic Acids Res 32: 2396-2410 [Abstract] [Full Text]
Trojanek, J., Ho, T., Del Valle, L., Nowicki, M., Wang, J. Y., Lassak, A., Peruzzi, F., Khalili, K., Skorski, T., Reiss, K. (2003). Role of the Insulin-Like Growth Factor I/Insulin Receptor Substrate 1 Axis in Rad51 Trafficking and DNA Repair by Homologous Recombination. Mol. Cell. Biol. 23: 7510-7524 [Abstract] [Full Text]
Biroccio, A., Benassi, B., Filomeni, G., Amodei, S., Marchini, S., Chiorino, G., Rotilio, G., Zupi, G., Ciriolo, M. R. (2002). Glutathione Influences c-Myc-induced Apoptosis in M14 Human Melanoma Cells. J. Biol. Chem. 277: 43763-43770 [Abstract] [Full Text]
Slupianek, A., Hoser, G., Majsterek, I., Bronisz, A., Malecki, M., Blasiak, J., Fishel, R., Skorski, T. (2002). Fusion Tyrosine Kinases Induce Drug Resistance by Stimulation of Homology-Dependent Recombination Repair, Prolongation of G2/M Phase, and Protection from Apoptosis. Mol. Cell. Biol. 22: 4189-4201 [Abstract] [Full Text]
Stewart, D. A., Xu, X., Thomas, S. D., Miller, D. M. (2002). Acridine-modified, clamp-forming antisense oligonucleotides synergize with cisplatin to inhibit c-Myc expression and B16-F0 tumor progression. Nucleic Acids Res 30: 2565-2574 [Abstract] [Full Text]
McGuffie, E. M., Pacheco, D., Carbone, G. M. R., Catapano, C. V. (2000). Antigene and Antiproliferative Effects of a c-myc-targeting Phosphorothioate Triple Helix-forming Oligonucleotide in Human Leukemia Cells. Cancer Res. 60: 3790-3799 [Abstract] [Full Text]
Nieborowska-Skorska, M., Wasik, M. A., Slupianek, A., Salomoni, P., Kitamura, T., Calabretta, B., Skorski, T. (1999). Signal Transducer and Activator of �Transcription (STAT)5 Activation by BCR/ABL Is Dependent on Intact Src Homology (SH)3 and SH2 Domains of BCR/ABL and Is Required for Leukemogenesis. J. Exp. Med. 189: 1229-1242 [Abstract] [Full Text]
Maran, A., Waller, C. F., Paranjape, J. M., Li, G., Xiao, W., Zhang, K., Kalaycio, M. E., Maitra, R. K., Lichtin, A. E., Brugger, W., Torrence, P. F., Silverman, R. H. (1998). 2',5'-Oligoadenylate-Antisense Chimeras Cause RNase L to Selectively Degrade bcr/abl mRNA in Chronic Myelogenous Leukemia Cells. Blood 92: 4336-4343 [Abstract] [Full Text]